Oral ONC201 in Adult Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Oncoceutics
- 29 Mar 2017 According to an Oncoceutics media release, results from the first cohort of patients will be reported in scientific forums throughout this year.
- 29 Mar 2017 According to an Oncoceutics media release, Massachusetts General Hospital (MGH) and the Dana Farber Cancer Institute are now enrolling patients in an expansion of the clinical trial in adult recurrent glioblastoma.
- 19 Mar 2017 Planned number of patients changed from 66 to 53.